What Spruce Street Capital LP reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 2050194 · Filed Nov 13, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 1.4M |
| +2.1% |
| $53.9M |
| 8.6% |
RLAYRelay Therapeutics, Inc. | 3M | ±0% | $53.9M | 8.6% |
ANROAlto Neuroscience, Inc. | 1.7M | +23.9% | $42.8M | 6.8% |
ALKSAlkermes plc. | 948.5K | +74.4% | $38.4M | 6.1% |
ENTXEntera Bio Ltd. | 11.2M | New | $32.6M | 5.2% |
DNTHDianthus Therapeutics, Inc. | 354.8K | ±0% | $31.2M | 5% |
SVRASavara Inc | 5.4M | +55.9% | $27.8M | 4.4% |
ZLABZai Lab Ltd | 1M | +273.4% | $27.5M | 4.4% |
RLMDRelmada Therapeutics, Inc. | 6.9M | +8.1% | $26.1M | 4.1% |
PCVXVaxcyte, Inc. | 306K | ±0% | $17.4M | 2.8% |
OBXObsidian Therapeutics, Inc. | 1.2M | New | $17.2M | 2.7% |
ELVNEnliven Therapeutics, Inc. | 329K | ±0% | $15.1M | 2.4% |
ENTAEnanta Pharmaceuticals Inc | 1.1M | ±0% | $14.3M | 2.3% |
SRZNSurrozen, Inc. | 432K | ±0% | $13.9M | 2.2% |
SGMTSagimet Biosciences Inc. | 1.4M | New | $13.8M | 2.2% |
YARWYarrow Bioscience, Inc. | 607.4K | New | $13.7M | 2.2% |
IFRXInflaRx N.V. | 6.1M | +13.7% | $11M | 1.7% |
KRSAKorsana Biosciences, Inc. | 339K | New | $10.3M | 1.6% |
CATXPerspective Therapeutics, Inc. | 3.7M | ±0% | $10.2M | 1.6% |
ANTXAN2 Therapeutics, Inc. | 1.8M | +5.5% | $9.3M | 1.5% |
IKTInhibikase Therapeutics, Inc. | 3.6M | ±0% | $7.4M | 1.2% |
SABSSAB Biotherapeutics, Inc. | 2.2M | ±0% | $7M | 1.1% |
IPSCCentury Therapeutics, Inc. | 4.1M | ±0% | $6.9M | 1.1% |
ERASErasca, Inc. | 422.5K | ±0% | $6.2M | 1% |
ACHVAchieve Life Sciences, Inc. | 736.6K | ±0% | $6M | 0.9% |
NERVMinerva Neurosciences, Inc. | 1.7M | ±0% | $5.5M | 0.9% |
RACCResearch Alliance Corp III | 500K | ±0% | $5.4M | 0.9% |
RACDResearch Alliance Corp IV | 450K | New | $5.4M | 0.9% |
HLXCHelix Acquisition Corp. III | 500K | ±0% | $5.3M | 0.8% |
ATTOAttovia Therapeutics, Inc. | 228.3K | New | $3.9M | 0.6% |
ALECAlector, Inc. | 2.1M | ±0% | $3.9M | 0.6% |
TCGXTCGX Acquisition Corp. | 300K | New | $3.8M | 0.6% |
LXEOLexeo Therapeutics, Inc. | 928.6K | ±0% | $3.1M | 0.5% |
ALMSAlumis Inc. | 392.6K | ±0% | $2.9M | 0.5% |
CRVSCorvus Pharmaceuticals, Inc. | 231.6K | ±0% | $2.7M | 0.4% |
JATTJATT II Acquisition Corp. | 160K | ±0% | $1.8M | 0.3% |
JTTTJATT III Acquisition Corp | 150K | New | $1.7M | 0.3% |
LONALeonaBio, Inc. | 393.7K | ±0% | $1.4M | 0.2% |